At 9.2% CAGR, the North America Breast Cancer Therapeutics Market Is Projected to be Worth US$ 27,014.92 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the North America breast cancer therapeutics market was valued at US$ 13,346.87 million in 2022 and is expected to reach US$ 27,014.92 million by 2030, registering a CAGR of 9.2% from 2022 to 2030. Growing burden of breast cancer and launch of several diagnostics and screening programs are among the critical factors attributed to the North America breast cancer therapeutics market expansion.

Breast cancer is considered the most common cancer among women worldwide, and its incidence is increasing globally. Factors such as lifestyle changes, hormonal imbalances, genetic predisposition, and environmental factors contribute to the rising prevalence of breast cancer. According to WHO, in 2020, 685,000 people died worldwide from breast cancer, accounting for 2.3 million new diagnoses. Breast cancer is one of the most common cancers globally, with 7.8 million women alive as of the end of 2020 who had received a diagnosis within the previous five years. All across the world, breast cancer affects women at any age after adolescence. However, its prevalence rises with age.

Per the American Cancer Society, approximately 5-10% of all malignancies are caused by genes inherited from parents. Several cancer-predisposition genes have been discovered. For instance, mutations in the inherited cancer predisposition genes BRCA1 and BRCA2 raise the risk of getting certain malignancies, such as breast, ovarian, and prostate cancer.

Furthermore, breast cancer is one of the most common types of cancer in the US. A report published by Breastcancer.org in January 2022 stated that 1 in 8 women in the nation (or ~13%) will acquire invasive breast cancer over their lifetime. According to the same source, 287,850 new incidences of invasive breast cancer, along with 51,400 new cases of noninvasive (in situ) breast cancer, are anticipated to be detected in women in the US in 2022. In the same year, the country is anticipated to record ~2,710 additional cases of invasive breast cancer in men. Approximately 1 in 833 men might develop breast cancer in their lives. With the rise in breast cancer cases, there is an increasing need for effective and targeted therapies to improve patient outcomes. This has led to a surge in research and development activities in breast cancer therapeutics. Therefore, the growing burden of breast cancer drives the North America breast cancer therapeutics market.

On the contrary, high cost of diagnosis and treatment hampers the growth North America breast cancer therapeutics market.

Based on drug therapy, the North America breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held 62.5% share of the North America breast cancer therapeutics market in 2022, amassing US$ 8,343.01 million. It is projected to garner US$ 17,427.64 million by 2030 to expand at 9.6% CAGR during 2022-2030. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the North America breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held 63.4% share of the North America breast cancer therapeutics market in 2022, amassing US$ 8,461.94 million. It is projected to garner US$ 17,652.90 million by 2030 to expand at 9.6% CAGR during 2022-2030.

By distribution channel, the North America breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held 70.2% share of North America breast cancer therapeutics market in 2022, amassing US$ 9,367.08 million. It is projected to garner US$ 19,326.80 million by 2030 to expand at 9.5% CAGR during 2022-2030.

Based on country, the North America breast cancer therapeutics market is categorized into US, Canada, and Mexico. The US held 83.6% share of North America breast cancer therapeutics market in 2022, amassing US$ 11,159.40 million. It is projected to garner US$ 23,043.37 million by 2030 to expand at 9.5% CAGR during 2022-2030.

Key players operating in the North America breast cancer therapeutics market are Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc, among others.

- In Jul 2021, Pfizer Inc. and Arvinas, Inc. entered into a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is in a Phase 2 dose expansion clinical trial for treating patients with ER+/HER2- locally advanced or metastatic breast cancer. Under the agreements terms, Pfizer paid Arvinas US$ 650 million upfront. Separately, Pfizer made a US$ 350 million equity investment in Arvinas. The companies will share worldwide development costs, commercialization expenses, and profits equally.

- In Mar 2023, Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with HR+/HER2- early breast cancer at risk of recurrence. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III early breast cancer regardless of nodal involvement.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com